Chris Cargill, Sosei Heptares CEO

With some neu­ro tar­gets in mind, Ab­b­Vie gets So­sei's drug dis­cov­ery en­gine churn­ing again

Ab­b­Vie has got more work for So­sei Hep­tares.

A year and a half af­ter break­ing off a lega­cy Al­ler­gan pact in­volv­ing a slate of So­sei neu­rol­o­gy can­di­dates, Ab­b­Vie has drawn up a whole slew of new neu­ro tar­gets it wants to di­rect So­sei’s G pro­tein-cou­pled re­cep­tor ex­per­tise and struc­ture-based drug de­sign savvi­ness to­ward.

The heav­i­ly back-end­ed deal starts with a $40 mil­lion up­front and $40 mil­lion more in near-term mile­stones but is tied to biobucks adding up to $1.2 bil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.